This is general educational content. Personal health decisions should involve a qualified clinician familiar with your medical history.
Can an older adult lose significant weight under medical supervision without sacrificing skeletal muscle? The question has haunted clinical obesity management for decades. A 2019 trial of semaglutide in patients over 65 reported that lean mass loss accounted for nearly 40% of total weight reduction in some participants. That number, if it holds across larger populations, represents a serious problem. Muscle is not merely a locomotive tissue. It is a metabolic organ, a reservoir of amino acids, a determinant of insulin sensitivity. Lose too much of it, and the very metabolic improvements that GLP-1 agonists are supposed to deliver begin to erode. The search for adjunctive strategies has turned, somewhat unexpectedly, toward the mitochondrial peptide MOTS-c.
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. It was first characterized in 2015 by a group at the University of Southern California, though Soviet researchers had speculated about mitochondrial-derived signaling molecules as early as the 1970s. In a 1982 issue of Biokhimiya, a Leningrad team described a low-molecular-weight factor from rat liver mitochondria that appeared to modulate glucose uptake in isolated diaphragm muscle. The work was discontinued after funding collapsed in 1986. The peptide they were likely observing, or something close to it, is now understood to translocate to the nucleus under metabolic stress and regulate adaptive gene expression. MOTS-c, in particular, activates AMPK and increases glucose utilization in skeletal muscle, effects that are especially relevant when systemic energy intake drops sharply.
GLP-1 receptor agonists, from liraglutide to tirzepatide, suppress appetite and slow gastric emptying. They produce weight loss that is, in many cases, remarkable. But the composition of that weight loss varies. Older adults already contend with age-related sarcopenia. Adding pharmacologically induced caloric restriction can accelerate muscle protein breakdown if countermeasures are not in place. Resistance training helps. Adequate protein intake helps. Yet neither fully addresses the mitochondrial dysfunction that underlies anabolic resistance in aging muscle. This is where MOTS-c enters the conversation. Not as a replacement for exercise or nutrition, but as a mitochondrial primer, a way to improve the metabolic efficiency of muscle cells so that they are less likely to be catabolized during energy deficit.
A 2022 review in Mitochondrion summarized the known mechanisms. MOTS-c accumulates in skeletal muscle following exercise and, in cell models, promotes myoblast differentiation. It also inhibits the folate cycle at a specific point, which leads to accumulation of AICAR, a known AMPK activator. The net effect is a shift toward oxidative metabolism and away from glycolytic dependency. For an older adult on a GLP-1 agonist, whose muscle cells may already be struggling with mitochondrial density loss, this shift could be protective. Or maybe not. The concern, articulated in a 2023 commentary by a group at the University of Copenhagen, is that MOTS-c might increase energy expenditure at a time when the whole organism is being pushed toward negative energy balance. Could that accelerate weight loss but worsen muscle loss? The data are not yet clear.
What does exist is a small but growing body of preclinical work. In a 2020 study, mice fed a high-fat diet and then treated with a GLP-1 analog plus MOTS-c showed preserved hindlimb muscle mass compared to those receiving the analog alone. Grip strength was higher. Mitochondrial DNA copy number in gastrocnemius tissue was higher. The combination appeared to blunt the rise in myostatin that typically accompanies rapid weight loss. Myostatin, a negative regulator of muscle growth, is upregulated in several catabolic states. If MOTS-c can suppress it, even modestly, the implications for older adults are significant. But mice are not humans. The translational gap is wide.
Another angle involves NAD+. Mitochondrial function depends on adequate NAD+ levels, which decline with age. MOTS-c has been shown to increase NAD+ synthesis in certain tissues, possibly through its effects on the salvage pathway. This connects to a broader discussion about NAD+ and cellular senescence. When NAD+ drops, senescent cells accumulate, and muscle repair falters. A 2021 experiment using human primary myotubes from donors aged 70 to 80 found that MOTS-c treatment increased NAD+ levels by approximately 30% and reduced markers of senescence-associated secretory phenotype. The authors suggested that the peptide might help maintain a more youthful mitochondrial network in aged muscle. If that holds true in vivo, then combining MOTS-c with a GLP-1 agonist could address two distinct but overlapping problems: excess adiposity and age-related mitochondrial decay.
There is also the matter of bone. Weight loss, particularly rapid weight loss, can reduce bone mineral density. Older adults are already at risk for osteoporosis. Some researchers have asked whether mitochondrial peptides might influence bone metabolism. The link is indirect but plausible. MOTS-c improves insulin sensitivity, and insulin is an anabolic hormone for bone. In a 2023 rodent study, MOTS-c administration was associated with increased osteoblast activity in the trabecular bone of the femur. The effect was modest and disappeared when the peptide was stopped. Still, it raises the possibility that a mitochondrial strategy could have benefits beyond muscle. This connects to the often-overlooked relationship between NAD+ and bone density, where similar mechanisms may be at play.
Other mitochondrial peptides deserve mention, if only to contextualize the field. Humanin, another peptide encoded in the mitochondrial genome, has been studied for its neuroprotective and metabolic effects. A 2018 trial in Japan tested a humanin analog in patients with type 2 diabetes and observed a small but statistically significant reduction in HbA1c. The trial was discontinued after phase II due to manufacturing difficulties, not lack of efficacy. Humanin and MOTS-c share some signaling pathways but differ in tissue distribution. Humanin appears more active in the brain and vasculature. MOTS-c is more muscle-focused. The distinction matters when the goal is muscle preservation during weight loss.
Then there are the synthetic peptides developed in the late Soviet period. Epitalon, a tetrapeptide designed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, was shown in a series of experiments from the 1980s and 1990s to activate telomerase and extend lifespan in mice. A 2003 publication in Bulletin of Experimental Biology and Medicine reported that Epitalon reduced the incidence of spontaneous tumors in aged rats. Cortagen, another Khavinson peptide, was investigated for its effects on brain function. Neither peptide directly targets mitochondria in the way MOTS-c does, but the Soviet approach, which emphasized bioregulation through short peptides, anticipated some of the current interest in mitochondrial-derived peptides. GHK-Cu, a copper-binding peptide first isolated from human plasma in 1973, has been studied for wound healing and, more recently, for its effects on gene expression related to tissue remodeling. A 2010 study found that GHK-Cu upregulated several mitochondrial genes in dermal fibroblasts. Vesugen, a vascular peptide, was tested in a small 1995 trial for retinal protection in diabetic patients. The results were inconclusive. None of these compounds has been tested in combination with GLP-1 agonists for muscle preservation, but the conceptual framework, that short peptides can modulate tissue-specific functions, is the same.
The active research on MOTS-c and GLP-1 agonists is concentrated in a few laboratories. One group at the University of Texas is conducting a pilot study combining semaglutide with a MOTS-c analog in adults aged 60 to 75 with obesity. The primary endpoint is change in appendicular lean mass as measured by DXA. Secondary endpoints include muscle strength, insulin sensitivity, and mitochondrial respiration in peripheral blood mononuclear cells. Results are expected in 2025. A separate team in South Korea is investigating whether MOTS-c levels in serum can predict muscle loss during GLP-1 therapy. Their preliminary data, presented at a 2023 conference, suggest that patients with lower baseline MOTS-c lose more lean mass, but the sample size was small. If validated, this could lead to a stratified approach: measure MOTS-c, identify high-risk patients, and intervene.
The gaps are substantial. First, the pharmacokinetics of MOTS-c in older adults are unknown. The peptide has a short half-life in circulation, on the order of minutes. Whether intermittent dosing can produce sustained mitochondrial effects is unclear. Second, the interaction between MOTS-c and GLP-1 receptor signaling has not been mapped at the molecular level. Both pathways converge on AMPK, but they may also have antagonistic effects on mTOR, a key regulator of muscle protein synthesis. Third, the long-term safety of MOTS-c administration is unstudied. Mitochondrial peptides are endogenously produced, but exogenous administration could, in theory, disrupt feedback loops. Fourth, the optimal timing of MOTS-c relative to meals and GLP-1 dosing is unexplored. Fifth, the role of exercise as a confounder is immense. MOTS-c is released during physical activity. If patients exercise more while losing weight, their endogenous MOTS-c may rise, making exogenous supplementation redundant. Or perhaps the combination of exercise and exogenous MOTS-c is synergistic. No one knows.
There is also the question of mitochondrial DNA repair. MOTS-c has been linked to the maintenance of mitochondrial genome integrity. A 2022 paper in Nucleic Acids Research showed that MOTS-c can localize to mitochondria under oxidative stress and interact with TFAM, a protein involved in mtDNA packaging and repair. This suggests a role beyond metabolism, one that touches on the fundamental stability of the mitochondrial genome. For older adults, whose mtDNA accumulates deletions with age, this could be relevant. The connection to MOTS-c and mitochondrial DNA repair is an emerging area of research that may eventually inform how we think about muscle aging.
The Soviet literature, for all its obscurity, offers a cautionary note. In a 1987 dissertation from the Institute of Gerontology in Kiev, a researcher named Oksana Petrovna described a peptide fraction from bovine mitochondria that, when injected into old rats, improved their swimming endurance but also caused a transient increase in core body temperature. The work was never published in a peer-reviewed journal. It exists only as a typewritten manuscript in a library that may no longer exist. The point is not that MOTS-c is dangerous. It is that mitochondrial interventions have a history of producing unexpected systemic effects. The mitochondrion is not an isolated organelle. It communicates with the nucleus, with other organelles, with the extracellular environment. Tweak one part of the network, and the whole system may respond in ways that are hard to predict.
Still, the rationale for combining MOTS-c with GLP-1 agonists in older adults is stronger than the rationale for many other combinations currently being explored. The biology is coherent. The preclinical data are suggestive. The clinical need is urgent. What is missing is the human evidence. Until the ongoing trials report, the discussion remains speculative. But speculation, when grounded in mechanism, is not without value. It directs attention to the right questions. How do we lose fat without losing muscle? How do we preserve mitochondrial function in the face of caloric restriction? How do we age without surrendering our metabolic resilience? These are not new questions. They were asked, in different language, by the Soviet biochemists who first probed mitochondrial extracts. They are being asked again now, with better tools and greater precision. The answers may finally be within reach.